Gregory Flippo, MD
Internal Medicine · Trussville, ALNPI 1033187109
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 276 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 49 manufacturers, the largest accounting for just 14.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,811 and has fallen 75.7% since, to $440 in 2025.
Across 276 payments — averaging $20.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merz North America, Inc.$821
- AbbVie$674
- AstraZeneca$353
- Johnson & Johnson$312
- Pfizer$302
- Lundbeck LLC$287
- plus $3K from 43 others
Across 175 payments — averaging $9386.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$889K
- Upsher-smith Laboratories LLC$183K
- AbbVie$161K
- Endo Pharmaceuticals Inc.$138K
- Kowa Research Institute, Inc.$104K
- AstraZeneca$59K
- plus $108K from 6 others
What the payments were for
- Food & beverage$5,768100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,768 in reported general payments places this provider in the 85th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,752 | $359,605 |
| AustedoDeutetrabenazine | 69 | $252,550 |
| IngrezzaValbenazine Tosylate | 41 | $164,046 |
| XifaxanRifaximin | 131 | $109,854 |
| RexultiBrexpiprazole | 196 | $76,536 |
| JardianceEmpagliflozin | 168 | $73,150 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 82 | $58,381 |
| XareltoRivaroxaban | 264 | $56,495 |
| OzempicSemaglutide | 62 | $55,601 |
| TrulicityDulaglutide | 74 | $47,213 |
| LinzessLinaclotide | 58 | $41,154 |
| TradjentaLinagliptin | 229 | $30,216 |
| JanuviaSitagliptin Phosphate | 156 | $28,917 |
| Atorvastatin Calcium | 2,922 | $26,988 |
| Potassium Chloride | 2,035 | $20,601 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $302 | $359,6051,752 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $34 | $252,55069 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $73 | $109,854131 claims |
| Boehringer IngelheimJardiance, Tradjenta | $186 | $103,366397 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $79 | $84,719145 claims |
| Novo NordiskOzempic, Levemir, Novolog | $279 | $81,103297 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $97 | $76,536196 claims |
| AbbVieLinzess, Namzaric | $674 | $59,634171 claims |
| Johnson & JohnsonXarelto | $312 | $56,495264 claims |
| Lilly USA, LLCTrulicity | $76 | $47,21374 claims |
| MerckJanuvia | $191 | $28,917156 claims |
| NovartisEntresto | $40 | $20,467119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Trussville
- Ryan WeldonBirmingham$458K
- Thomas McKelveyMobile$365K
- Mary HonkanenMobile$302K
- Robert LewisBirmingham$187K
- Rosalind BowlesGadsden$168K
- Sonja PettusJasper$117K
- Bobby WrightsMobile$89K
- Thomas HuddleBirmingham$76K
- Rahel AzizMobile$67K
- Justin HoveyDothan$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.